Skip to main content
Tempest Therapeutics, Inc. logo

Tempest Therapeutics, Inc. — Investor Relations & Filings

Ticker · TPST ISIN · US69014Q1013 US Professional, scientific and technical activities
Open in API
Filings indexed 986 across all filing types
Latest filing 2014-09-19 Major Shareholding Noti…
Country US United States of America
Listing US TPST

About Tempest Therapeutics, Inc.

https://www.tempesttx.com/

Tempest Therapeutics, Inc. is a clinical-stage oncology company advancing a diverse portfolio of small molecule product candidates and cell therapies. The company develops first-in-class therapeutics that combine tumor-targeted and immune-mediated mechanisms to treat cancer. Its lead product candidate is amezalpat (TPST-1120), an oral, selective PPARα antagonist being evaluated in a global, randomized combination study for hepatocellular carcinoma. In addition to its small molecule platform, the company is also developing dual-chimeric antigen receptor (CAR) T-cell programs.

Recent filings

Filing Released Lang Actions
SC 13D/A
Major Shareholding Notification
2014-09-19 English
4
Director's Dealing
2014-09-19 English
4
Director's Dealing
2014-09-18 English
3
Director's Dealing
2014-09-18 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated September 18, 2014. It reports the appointment of a new Chief Financial Officer and Treasurer, Jeffrey E. Young, including details about his compensation and stock options. The document includes sections titled 'Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers' and 'Item 9.01 Financial Statements and Exhibits.' The content focuses on management changes and related disclosures. There are no financial statements or earnings data presented, nor is this a report of voting results or a regulatory announcement unrelated to management. The primary subject is the appointment of a senior officer, which fits the category of Board/Management Information (MANG). The document length (7343 characters) and detailed description of the appointment support this classification rather than a brief announcement or a different category.
2014-09-18 English
4
Director's Dealing
2014-08-28 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.